ZSH-2208: A novel retinoid with potent anti-tumour effects on ESCC stem cells via RARγ-TNFAIP3 axis.

Clin Transl Med · 2025 · PMC11670471 · PMID 39724264

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

The expression of TNFAIP3 at both the protein and gene levels in ESCC‐TRCs treated with ZSH‐2208 showed a decreasing trend, as well as its binding protein TNIP1, with increasing doses of ZSH‐2208 (Figures 4I and S5I,J ), which is consistent with the dose‐dependent inhibitory effect of ZSH‐2208 on RARγ observed in previous in vitro experiments.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.